In 130 adults with KMT2A-rearranged leukaemia undergoing allogeneic HSCT in China, adding decitabine to busulfan-cyclophosphamide conditioning lowered 2-year relapse (12% vs 29%; HR 0·41, p=0·017), with similar grade 3–5 adverse events.
RCTn = 130
Hu et al. Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial